UY25044A1 - Utilizacion de inhibidores selectivos directos o indirectos del factor xa solos o en combinacion con un compuesto antiagregante plaquetario y composiciones destinadas a prevenir y tratar las enfermedades tromboembólicas arteriales - Google Patents

Utilizacion de inhibidores selectivos directos o indirectos del factor xa solos o en combinacion con un compuesto antiagregante plaquetario y composiciones destinadas a prevenir y tratar las enfermedades tromboembólicas arteriales

Info

Publication number
UY25044A1
UY25044A1 UY25044A UY25044A UY25044A1 UY 25044 A1 UY25044 A1 UY 25044A1 UY 25044 A UY25044 A UY 25044A UY 25044 A UY25044 A UY 25044A UY 25044 A1 UY25044 A1 UY 25044A1
Authority
UY
Uruguay
Prior art keywords
direct
factor
selective inhibitors
prevent
phenyl
Prior art date
Application number
UY25044A
Other languages
English (en)
Inventor
Ronald Van Amsterdam
Jean Marc Herbert
Andre Bernat
Maurice Petitou
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of UY25044A1 publication Critical patent/UY25044A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

La presente invención se refiere a composiciones farmacéuticas que contienen uno o varios inhibidores selectivos directos o indirectos del factor Xa que actúan vía la antotrombina III, en asociación con uno o varios compuestos de actividad antiagregante plaquetaria, elegidos del grupo que comprende aspirina, ticlopidina, clopidogrel y antagonistas de la glicoproteína IIb/IIIa, y eventualmente uno o varios vehículos farmacéuticamente aceptables; y a la utilización de los mismos, destinados a prevenir y a tratar las enfermedades tromboembólicas arteriales. Dentro de los inhibidores selectivos directos el preferido es el ácido (2S)-2-(4-(((3S)-1-acetimidoil-3-pirrolidinil)oxi)fenil)-3-(7-amidino-2-naftil)propanoico de estructura (A) (ver figura) o una de sus sales farmacéuticamente aceptables. El agonista de la glicoproteína IIb/IIIa está elegido entre N-(1-etoxicarbonilmetil-piperidin-4-il)-N-(4-(4-(N-etoxicarbonilimino)-(amino)metil)-fenil)-tiazol-2-il)-3-amino propionato de etilo; ácido N-(1-carboximetil-piperidin-4-il)-N-(4-(4-((amino)(imino)metil)fenil)-tiazol-2-il)-3-aminopropiónico, y sus sales farmacéuticamente aceptables. El inhibidor indirecto del factor Xa es un oligosacárido También es objeto de la invención, las composiciones farmacéuticas que contienen uno o varios de los mencionados inhibidores selectivos.
UY25044A 1997-06-13 1998-06-12 Utilizacion de inhibidores selectivos directos o indirectos del factor xa solos o en combinacion con un compuesto antiagregante plaquetario y composiciones destinadas a prevenir y tratar las enfermedades tromboembólicas arteriales UY25044A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9707368A FR2764511B1 (fr) 1997-06-13 1997-06-13 Compositions pour le traitement et la prevention de la thrombose arterielle et utilisation d'un inhibiteur du facteur xa seul et/ou en combinaison avec un antiagregant plaquettaire

Publications (1)

Publication Number Publication Date
UY25044A1 true UY25044A1 (es) 2000-10-31

Family

ID=9507960

Family Applications (1)

Application Number Title Priority Date Filing Date
UY25044A UY25044A1 (es) 1997-06-13 1998-06-12 Utilizacion de inhibidores selectivos directos o indirectos del factor xa solos o en combinacion con un compuesto antiagregante plaquetario y composiciones destinadas a prevenir y tratar las enfermedades tromboembólicas arteriales

Country Status (43)

Country Link
US (2) US6541488B1 (es)
EP (1) EP0986376B1 (es)
JP (1) JP3988803B2 (es)
KR (1) KR100598451B1 (es)
CN (1) CN1253150C (es)
AR (1) AR012247A1 (es)
AT (1) ATE384528T1 (es)
AU (1) AU728826B2 (es)
BR (1) BR9810520A (es)
CA (1) CA2293415C (es)
CO (1) CO4940476A1 (es)
CY (1) CY1107912T1 (es)
CZ (1) CZ299518B6 (es)
DE (1) DE69839046T2 (es)
DK (1) DK0986376T3 (es)
DZ (1) DZ2512A1 (es)
EE (1) EE04737B1 (es)
ES (1) ES2299209T3 (es)
FR (1) FR2764511B1 (es)
GT (1) GT199800171A (es)
HK (1) HK1032750A1 (es)
HR (1) HRP980322B1 (es)
HU (1) HU227956B1 (es)
ID (1) ID29309A (es)
IL (1) IL133452A (es)
IS (1) IS2619B (es)
ME (1) ME00685B (es)
MY (1) MY124648A (es)
NO (1) NO323739B1 (es)
NZ (1) NZ501452A (es)
PL (1) PL193405B1 (es)
PT (1) PT986376E (es)
RS (1) RS49902B (es)
RU (1) RU2212886C2 (es)
SA (1) SA98190552B1 (es)
SI (1) SI0986376T1 (es)
SK (1) SK286311B6 (es)
TR (1) TR199903087T2 (es)
TW (1) TW565442B (es)
UA (1) UA70919C2 (es)
UY (1) UY25044A1 (es)
WO (1) WO1998056365A1 (es)
ZA (1) ZA985137B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2764511B1 (fr) * 1997-06-13 2000-09-08 Sanofi Sa Compositions pour le traitement et la prevention de la thrombose arterielle et utilisation d'un inhibiteur du facteur xa seul et/ou en combinaison avec un antiagregant plaquettaire
EP1156803A4 (en) 1999-02-09 2004-03-17 Bristol Myers Squibb Co FXA LACTAM INHIBITORS AND METHOD
US6344450B1 (en) 1999-02-09 2002-02-05 Bristol-Myers Squibb Company Lactam compounds and their use as inhibitors of serine proteases and method
FR2793687B1 (fr) * 1999-04-26 2001-08-24 Sanofi Sa Nouvelle composition injectable d'un anticoagulant
FR2800074B1 (fr) * 1999-10-22 2001-12-21 Aventis Pharma Sa Nouveaux oligosaccharides, leur preparation et les compositions pharmaceutiques les contenant
US6544981B2 (en) 2000-06-09 2003-04-08 Bristol-Myers Squibb Company Lactam inhibitors of factor Xa and method
US6511973B2 (en) 2000-08-02 2003-01-28 Bristol-Myers Squibb Co. Lactam inhibitors of FXa and method
WO2002102325A2 (en) * 2001-02-28 2002-12-27 Griffin John H Plasma glucosylceramide deficiency as risk factor for thrombosis and modulator of anticoagulant protein c
UA80399C2 (en) * 2001-11-13 2007-09-25 Glaxo Group Ltd Use of specific dose of fondaparinux sodium for the treatment of acs
AU2003270861A1 (en) 2002-10-02 2004-04-23 Bristol-Myers Squibb Company Novel combination of a factor xa inhibitor and clopidogrel
US20070004736A1 (en) * 2002-11-22 2007-01-04 Keiji Kubo Imidazole derivative, process for producing the same, and use
JP4855073B2 (ja) * 2003-09-19 2012-01-18 キッセイ薬品工業株式会社 併用医薬
WO2005087266A1 (en) * 2004-03-05 2005-09-22 Vddi Pharmaceuticals Combination therapy for inhibition of platelet aggregation
KR101099884B1 (ko) * 2004-04-23 2011-12-28 히또시 기야 동화상데이터의 부호화방법, 복호화방법, 이들을 실행하는단말장치, 및 쌍방향 대화형 시스템
TWI396686B (zh) * 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
US7563780B1 (en) * 2004-06-18 2009-07-21 Advanced Cardiovascular Systems, Inc. Heparin prodrugs and drug delivery stents formed therefrom
JP5557410B2 (ja) * 2004-07-13 2014-07-23 第一三共株式会社 経口投与による血栓・塞栓の予防治療剤
US20070105825A1 (en) * 2004-09-16 2007-05-10 Yuji Hoyano Concurrent drugs
CA2624867A1 (en) * 2005-10-10 2007-04-19 N.V. Organon Antithrombotic compound
US20110150976A1 (en) * 2008-09-10 2011-06-23 Transpharma Medical Ltd. Transdermal delivery of oligosaccharides
WO2011149110A1 (en) 2010-05-28 2011-12-01 Daiichi Sankyo Company, Limited Novel composition for the prevention and/or treatment of thromboembolism
JP6389009B2 (ja) * 2014-10-30 2018-09-12 チェンデュ バイユ ファーマシューティカル カンパニー リミテッドＣｈｅｎｇｄｕ Ｂａｉｙｕ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．，Ｌｔｄ． ギンコライドＢと第Ｘａ因子阻害剤とを含有する薬物組成物及びその製造方法と用途
CN106860868B (zh) * 2015-12-11 2019-11-22 北京百奥药业有限责任公司 沙班类药物与蚓激酶的药物组合物、制剂及其应用
US11654036B2 (en) 2020-05-26 2023-05-23 Elixir Medical Corporation Anticoagulant compounds and methods and devices for their use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2548189B1 (fr) * 1983-07-01 1986-04-11 Choay Sa Nouveaux produits contenant des oligosaccharides, leur preparation et leurs applications biologiques et biochimiques
ZA928276B (en) * 1991-10-31 1993-05-06 Daiichi Seiyaku Co Aromatic amidine derivates and salts thereof.
FR2728901B1 (fr) * 1994-12-28 1997-03-28 Sanofi Sa Derives de phenyl-4-thiazoles substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
BR9713141A (pt) 1996-11-27 2000-02-08 Rhone Poulenc Rorer Pharma Composição farmcêutica processo e kit para o tratamento ou a prevenção de um quadro fisiológico asociado com um distúrbio isquêmico relacionado com trombose e um paciente, uso de quantidades farmaceuticamente efetivas de um composto com atividade anti-xa e de um composto antagonista de agregação de plaquetas, produto contendo estes compostos, e, uso destes compostos.
FR2764511B1 (fr) * 1997-06-13 2000-09-08 Sanofi Sa Compositions pour le traitement et la prevention de la thrombose arterielle et utilisation d'un inhibiteur du facteur xa seul et/ou en combinaison avec un antiagregant plaquettaire

Also Published As

Publication number Publication date
DE69839046T2 (de) 2009-01-15
CN1253150C (zh) 2006-04-26
JP3988803B2 (ja) 2007-10-10
CZ446099A3 (cs) 2000-04-12
AR012247A1 (es) 2000-09-27
TR199903087T2 (xx) 2000-05-22
EP0986376B1 (fr) 2008-01-23
FR2764511B1 (fr) 2000-09-08
CN1274281A (zh) 2000-11-22
TW565442B (en) 2003-12-11
PL193405B1 (pl) 2007-02-28
GT199800171A (es) 2000-04-21
AU7924698A (en) 1998-12-30
NO996137L (no) 2000-02-14
YU63699A (sh) 2002-06-19
PT986376E (pt) 2008-04-01
JP2002504110A (ja) 2002-02-05
SA98190552B1 (ar) 2006-09-09
HUP0002175A1 (hu) 2000-11-28
CA2293415C (en) 2011-08-09
DE69839046D1 (de) 2008-03-13
SK286311B6 (en) 2008-07-07
IL133452A (en) 2004-09-27
IS2619B (is) 2010-05-15
CA2293415A1 (en) 1998-12-17
ID29309A (id) 2001-08-16
AU728826B2 (en) 2001-01-18
PL337288A1 (en) 2000-08-14
IL133452A0 (en) 2001-04-30
NZ501452A (en) 2002-06-28
US6541488B1 (en) 2003-04-01
NO996137D0 (no) 1999-12-10
WO1998056365A1 (fr) 1998-12-17
RU2212886C2 (ru) 2003-09-27
HUP0002175A3 (en) 2003-05-28
DK0986376T3 (da) 2008-05-13
ZA985137B (en) 1999-01-07
EE9900574A (et) 2000-08-15
ES2299209T3 (es) 2008-05-16
CZ299518B6 (cs) 2008-08-20
KR100598451B1 (ko) 2006-07-10
NO323739B1 (no) 2007-07-02
SK170999A3 (en) 2000-07-11
HU227956B1 (en) 2012-07-30
HK1032750A1 (en) 2001-08-03
MY124648A (en) 2006-06-30
KR20010013690A (ko) 2001-02-26
DZ2512A1 (fr) 2003-02-01
RS49902B (sr) 2008-08-07
FR2764511A1 (fr) 1998-12-18
ATE384528T1 (de) 2008-02-15
EP0986376A1 (fr) 2000-03-22
SI0986376T1 (sl) 2008-06-30
UA70919C2 (uk) 2004-11-15
ME00685B (me) 2008-08-07
CY1107912T1 (el) 2013-09-04
US20040092477A1 (en) 2004-05-13
IS5280A (is) 1999-11-30
EE04737B1 (et) 2006-12-15
CO4940476A1 (es) 2000-07-24
HRP980322B1 (en) 2003-12-31
BR9810520A (pt) 2000-09-19
HRP980322A2 (en) 1999-04-30

Similar Documents

Publication Publication Date Title
UY25044A1 (es) Utilizacion de inhibidores selectivos directos o indirectos del factor xa solos o en combinacion con un compuesto antiagregante plaquetario y composiciones destinadas a prevenir y tratar las enfermedades tromboembólicas arteriales
CR7865A (es) Derivados de dihidropiranoindol -3,4-diona sustituidos y derivados de 2-hidroximetilindol del acido 3-oxoacetico sustituidos como inhibidores del inhibidor del activador del plasminogeno 1(pai-1)
PE20050342A1 (es) Tableta que contiene el ester etilico de acido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamino]-metil}-1-metil-1h-bencimidazol-5-carbonil)-piridin-2-il-amino]-propionico o sus sales
AR029766A1 (es) Compuesto inhibidor de quinasa y uso del mismo para preparar una composicion farmaceutica
AR054445A1 (es) Formulaciones de un inhibidor de src/abl
DK1663206T3 (da) 1-(2,3-dimethyl-phenyl)-ethyl-1,3-dihydro-imizadol-2-thion som ikke-sedativ alpha 2A-agonist
PE20121820A1 (es) (2s,3r)-n-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)benzofuran-2-carboxamida, formas de sales novedosas de ella, y metodos de uso de ella
EA200702498A1 (ru) N-(пиридин-2-ил)сульфонамидные производные
CO5600999A2 (es) Composiciones farmaceuticas que comprenden inhibidores de valsartan y endopeptidasa neutra
ATE442145T1 (de) Pharmazeutische zusammensetzung mit einem benzodiazepin-derivat und einem hemmer des rsv- fusionsproteins
AR047823A1 (es) Derivados de 1,2,3,4-tetrahidroisoquinolina sustituida
UY25242A1 (es) Inhibidores de benzotiazol de la proteína tirosina cinasa
PE20110062A1 (es) N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo
CO5611149A2 (es) Forma de presentacion para administracion por vial oral, que comprende ester etilico de acido 3-[(2-{[4-(hexiloxicarbonilo amino-imino-metil)-fenilamino]-metil}-1-metil-1h-bencilimi dazol-5-carbonil)-piridin-2-il-amino]-propionico y un nucleo que com
AR020065A1 (es) Uso de inhibidores de proteasas de cisteina para la fabricacion de un medicamento y composicion farmaceutica que los comprende
BR9714310A (pt) Composição farmacêutica
AR049274A1 (es) Acido2-{[2-(2-metilaminopirimidin-4-il)-1h-indol-5-carbonil]amino}-3-(fenilpiridin-2-ilamino)propionico sustancialmente puro como inhibidor selectivo de la quinasa ikk-2
AR012681A1 (es) Inhibidores de proteasas, composicion farmaceutica que los comprende, su uso para la fabricacion de un medicamento y compuesto intermediario
CO4970807A1 (es) Compuestos de indol 2,3 sustituidos como agentes anti-infla matorios y analgesicos
ES2191942T3 (es) Nueva utilizacion de un antagonista especifico de los receptores 5ht2a.
PE20040669A1 (es) Derivados de fenilalanina enamida
CO4990971A1 (es) Agentes terapeuticos selectivos de la mmp-3, especialmente con una buena selecti vidad con respecto a las mmp-1,2,9y/o 14
AR035133A1 (es) Composicion topica para suministro folicular de un inhibidor de ornitina descarboxilasa
AR044175A1 (es) Compuestos de cefemo
AR046719A1 (es) Sales de benzazepina y composiciones farmacéuticas que las contienen.

Legal Events

Date Code Title Description
VENC Patent expired

Effective date: 20180612